Preparation and in vitro – in vivo evaluation of teniposide nanosuspensions

He, Suna; Yang, Hui; Zhang, Ruizhi; Li, Yan; Duan, Leng‐Xin

doi:10.1016/j.ijpharm.2014.11.020

Cited by 25 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ho and Lee [ 120 ] did not study dissolution of spray-dried nanocomposites. He et al [ 160 ] and Kumar et al [ 139 ] corroborated the redispersion results with dissolution; teniposide and naproxen nanocomposite particles formulated with PVP K30 and HPMC E15 showed significantly improved dissolution.…”

Section: Preparation Characterization and Formulation Of Drug-lamentioning

confidence: 87%

“…In other studies such as He et al [ 160 ], Ho and Lee [ 120 ], and Kumar et al [ 139 ], drug nanoparticles were recovered from nanocomposites with soluble polymers that serve as stabilizers/dispersants. He et al [ 160 ] formed nanoparticles of teniposide in the presence of PVP K30 by antisolvent precipitation followed by freeze drying; Ho and Lee [ 120 ] milled naproxen down to the nanosize domain with HPC and formed nanocomposite particles by electrospray drying; and Kumar et al [ 139 ] wet-milled naproxen particles with HPMC E15 followed by spray drying to form nanocomposite particles. While the above-mentioned studies used different drugs and different particle formation–drying methods, the nanocomposites completely redispersed into nanoparticles during manual redispersion or sonication in less than 5 min.…”

Section: Preparation Characterization and Formulation Of Drug-lamentioning

confidence: 99%

See 1 more Smart Citation

Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation–Processing Aspects and Challenges

et al. 2018

View full text Add to dashboard Cite

Drug nanoparticles embedded in a dispersant matrix as a secondary phase, i.e., drug-laden nanocomposites, offer a versatile delivery platform for enhancing the dissolution rate and bioavailability of poorly water-soluble drugs. Drug nanoparticles are prepared by top-down, bottom-up, or combinative approaches in the form of nanosuspensions, which are subsequently dried to prepare drug-laden nanocomposites. In this comprehensive review paper, the term “nanocomposites” is used in a broad context to cover drug nanoparticle-laden intermediate products in the form of powders, cakes, and extrudates, which can be incorporated into final oral solid dosages via standard pharmaceutical unit operations, as well as drug nanoparticle-laden strip films. The objective of this paper is to review studies from 2012–2017 in the field of drug-laden nanocomposites. After a brief overview of the various approaches used for preparing drug nanoparticles, the review covers drying processes and dispersant formulations used for the production of drug-laden nanocomposites, as well as various characterization methods including quiescent and agitated redispersion tests. Traditional dispersants such as soluble polymers, surfactants, other water-soluble dispersants, and water-insoluble dispersants, as well as novel dispersants such as wet-milled superdisintegrants, are covered. They exhibit various functionalities such as drug nanoparticle stabilization, mitigation of aggregation, formation of nanocomposite matrix–film, wettability enhancement, and matrix erosion/disintegration. Major challenges such as nanoparticle aggregation and poor redispersibility that cause inferior dissolution performance of the drug-laden nanocomposites are highlighted. Literature data are analyzed in terms of usage frequency of various drying processes and dispersant classes. We provide some engineering considerations in comparing drying processes, which could account for some of the diverging trends in academia vs. industrial practice. Overall, this review provides rationale and guidance for drying process selection and robust nanocomposite formulation development, with insights into the roles of various classes of dispersants.

show abstract

Section: Preparation Characterization and Formulation Of Drug-lamentioning

confidence: 87%

Section: Preparation Characterization and Formulation Of Drug-lamentioning

confidence: 99%

Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation–Processing Aspects and Challenges

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Production of drug nanocrystals can be divided into two different approaches: (i) top-down and (ii) bottom-up techniques [ 5 , 12 , 13 ]. In top-down methods, particle size is decreased from coarse drug particles to nanoparticles, for example, by different kinds of wet milling or high-pressure homogenization techniques [ 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Design Space and QbD Approach for Production of Drug Nanocrystals by Wet Media Milling Techniques

Peltonen

2018

Pharmaceutics

View full text Add to dashboard Cite

Drug nanocrystals are nanosized solid drug particles, the most important application of which is the improvement of solubility properties of poorly soluble drug materials. Drug nanocrystals can be produced by many different techniques, but the mostly used are different kinds of media milling techniques; in milling, particle size of bulk sized drug material is decreased, with the aid of milling beads, to nanometer scale. Utilization of Quality by Design, QbD, approach in nanomilling improves the process-understanding of the system, and recently, the number of studies using the QbD approach in nanomilling has increased. In the QbD approach, the quality is built into the products and processes throughout the whole production chain. Definition of Critical Quality Attributes, CQAs, determines the targeted final product properties. CQAs are confirmed by setting Critical Process Parameters, CPPs, which include both process parameters but also input variables, like stabilizer amount or the solid state form of the drug. Finally, Design Space determines the limits in which CPPs should be in order to reach CQAs. This review discusses the milling process and process variables, CPPs, their impact on product properties, CQAs and challenges of the QbD approach in nanomilling studies.

show abstract

“…Male Wistar rats weighting 200 ±10 g were inoculated subcutaneously with 0.2 mL of C6 cells (5×10 6 /mL) at the right groin to obtain glioma models (He, Yang et al 2015). One week later, the C6 tumor-bearing rats were randomly divided into three groups (6 for 5 % glucose as control, 6 for VUMON, and 6 for TEN-SMEDDS), At Day 8, 10, 12, 14, 16, 18 and 20 after the inoculation, different formulations were given intravenously to each animal via tail vein.…”

Section: Wistar Rats Tumor Modelsmentioning

confidence: 99%

Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo

Cui

Wang

et al. 2015

International Journal of Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Preparation and in vitro – in vivo evaluation of teniposide nanosuspensions

Cited by 25 publications

References 31 publications

Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation–Processing Aspects and Challenges

Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation–Processing Aspects and Challenges

Design Space and QbD Approach for Production of Drug Nanocrystals by Wet Media Milling Techniques

Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo

Contact Info

Product

Resources

About